TRAF6通过与HDAC3互作增强c-Myc表达及蛋白稳定性促进肝癌发生
该研究揭示E3泛素连接酶TRAF6在肝癌发生中上调c-Myc:TRAF6对HDAC3进行K63连接泛素化,促使HDAC3从c-Myc启动子解离并增加H3K9乙酰化,从而增强c-Myc mRNA表达;同时该泛素化削弱HDAC3与c-Myc结合,促进c-Myc蛋白乙酰化并抑制其降解,提高蛋白稳定性。临床HCC样本中TRAF6高表达与不良预后相关,Traf6+/-小鼠肝肿瘤发生受损,TRAF6/HDAC3/c-Myc信号在HBV转基因小鼠中亦被启动,抑制TRAF6活性或沉默c-Myc可抑制小鼠肿瘤生长。
要点
- TRAF6通过K63泛素化HDAC3增强c-Myc mRNA表达并提高c-Myc蛋白稳定性。
- 临床HCC中TRAF6高表达与不良预后相关,TRAF6与c-Myc在mRNA和蛋白水平正相关。
- Traf6+/-小鼠肝肿瘤发生显著受损,抑制TRAF6活性或沉默c-Myc可抑制小鼠肿瘤生长。
核心结论
- TRAF6通过调控TRAF6/HDAC3/c-Myc信号在肝癌发生中发挥致癌潜力,对HCC治疗具有潜在意义。
研究设计与样本
- 基础与转化研究:临床HCC样本、Traf6+/-小鼠、HBV转基因小鼠及小鼠肿瘤模型。
主要发现
- 临床HCC样本中TRAF6高表达与不良预后相关,Traf6+/-小鼠肝肿瘤发生显著受损。
- TRAF6对HDAC3进行K63连接泛素化,导致HDAC3从c-Myc启动子解离并增加H3K9乙酰化,增强c-Myc mRNA表达。
- HDAC3的K63泛素化削弱其与c-Myc结合,促进c-Myc蛋白乙酰化并抑制CHIP介导的c-Myc泛素化降解,提高c-Myc蛋白稳定性。
- TRAF6/HDAC3/c-Myc信号在HBV转基因小鼠中亦被启动,提示其在炎症-癌转化中的作用。
- 临床标本中TRAF6与c-Myc在mRNA和蛋白水平正相关,TRAF6和c-Myc高表达与不良预后相关。
临床怎么用
- TRAF6/HDAC3/c-Myc信号轴可能成为HCC治疗的潜在干预靶点,TRAF6抑制剂肽或c-Myc siRNA在 mice 中抑制肿瘤生长。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The oncogene c-Myc is aberrantly expressed and plays a key role in malignant transformation and progression of hepatocellular carcinoma (HCC). Here, we report that c-Myc is significantly up-regulated by tumor necrosis factor receptor-associated factor 6 (TRAF6), an E3 ubiquitin ligase, in hepatocarcinogenesis. High TRAF6 expression in clinical HCC samples correlates with poor prognosis, and the loss of one copy of the Traf6 gene in Traf6+/- mice significantly impairs liver tumorigenesis. Mechanistically, TRAF6 first interacts with and ubiquitinates histone deacetylase 3 (HDAC3) with K63-linked ubiquitin chains, which leads to the dissociation of HDAC3 from the c-Myc promoter and subsequent acetylation of histone H3 at K9, thereby epigenetically enhancing the mRNA expression of c-Myc. Second, the K63-linked ubiquitination of HDAC3 impairs the HDAC3 interaction with c-Myc and promotes c-Myc protein acetylation, which thereby enhances c-Myc protein stability by inhibiting carboxyl terminus of heat shock cognate 70-kDa-interacting protein-mediated c-Myc ubiquitination and degradation. Importantly, TRAF6/HDAC3/c-Myc signaling is also primed in hepatitis B virus-transgenic mice, unveiling a critical role for a mechanism in inflammation-cancer transition. In clinical specimens, TRAF6 positively correlates with c-Myc at both the mRNA and protein levels, and high TRAF6 and c-Myc expression is associated with an unfavorable prognosis, suggesting that TRAF6 collaborates with c-Myc to promote human hepatocarcinogenesis. Consistently, curbing c-Myc expression by inhibition of TRAF6 activity with a TRAF6 inhibitor peptide or the silencing of c-Myc by small interfering RNA significantly suppressed tumor growth in mice. Conclusion: These findings demonstrate the oncogenic potential of TRAF6 during hepatocarcinogenesis by modulating TRAF6/HDAC3/c-Myc signaling, with potential implications for HCC therapy.
引用
- Wu H, Yang TY, Li Y, et al. Tumor Necrosis Factor Receptor-Associated Factor 6 Promotes Hepatocarcinogenesis by Interacting With Histone Deacetylase 3 to Enhance c-Myc Gene Expression and Protein Stability. Hepatology. 2019. PMID: 31155734. doi:10.1002/hep.30801
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。